Personalized neoantigen DNA vaccine GNOS-PV02 and pembrolizumab as second-line treatment for advanced hepatocellular carcinoma

被引：0
|
作者：
Yarchoan, Mark
Gane, Edward J.
Marron, Thomas U.
Perales-Linares, Renzo
Yan, Jian
Cooch, Neil
Shu, Daniel
Fertig, Elana J.
Kagohara, Luciane T.
Bartha, Gabor
Northcott, Josette
Lyle, John
Rochestie, Sarah
Peters, Joann
Connor, Jason
Jaffee, Elizabeth
Perales-Puchalt, Alfredo
Weiner, David B.
Csiki, Ildiko
Sardesai, Niranjan Y.
机构：
来源：
CANCER RESEARCH | 2024年 / 84卷 / 06期
关键词：
D O I：
10.1158/1538-7445.AM2024-1191
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1191
引用
收藏
页数：2
相关论文
共 50 条
  • [31] Efficacy and Tolerability of Second-line Pembrolizumab With Radiation Therapy in Advanced Urothelial Carcinoma
    Sano, Takeshi
    Aizawa, Rihito
    Ito, Katsuhiro
    Nakamura, Kiyonao
    Ogata, Takashi
    Takeda, Masashi
    Hamada, Akihiro
    Matsuoka, Takashi
    Kono, Jin
    Kita, Yuki
    Masui, Kimihiko
    Goto, Takayuki
    Sawada, Atsuro
    Akamatsu, Shusuke
    Ogawa, Osamu
    Mizowaki, Takashi
    Kobayashi, Takashi
    ANTICANCER RESEARCH, 2023, 43 (05) : 2119 - 2126
  • [32] Defining the Ideal Patient with Hepatocellular Carcinoma for Second-Line Treatment
    Roviello, Giandomenico
    Casadei-Gardini, Andrea
    Nobili, Stefania
    Mini, Enrico
    Fancelli, Sara
    JOURNAL OF ONCOLOGY, 2020, 2020
  • [33] Tivantinib, a new option for second-line treatment of advanced hepatocellular carcinoma? The experience of Italian centers
    Rimassa, Lorenza
    Santoro, Armando
    Daniele, Bruno
    Germano, Domenico
    Gasbarrini, Antonio
    Salvagni, Stefania
    Masi, Gianluca
    Abbadessa, Giovanni
    Lamar, Maria
    Goldberg, Terri
    Porta, Camillo
    TUMORI JOURNAL, 2015, 101 (02): : 139 - 143
  • [34] Role of regorafenib as second-line therapy and landscape of investigational treatment options in advanced hepatocellular carcinoma
    Trojan, Joerg
    Waidmann, Oliver
    JOURNAL OF HEPATOCELLULAR CARCINOMA, 2016, 3 : 31 - 36
  • [35] Characteristics of patients with sorafenib-treated advanced hepatocellular carcinoma eligible for second-line treatment
    Ogasawara, Sadahisa
    Chiba, Tetsuhiro
    Ooka, Yoshihiko
    Suzuki, Eiichiro
    Maeda, Takahiro
    Yokoyama, Masayuki
    Wakamatsu, Toru
    Inoue, Masanori
    Saito, Tomoko
    Kobayashi, Kazufumi
    Kiyono, Soichiro
    Nakamura, Masato
    Nakamoto, Shingo
    Yasui, Shin
    Tawada, Akinobu
    Arai, Makoto
    Kanda, Tatsuo
    Maruyama, Hitoshi
    Yokosuka, Osamu
    Kato, Naoya
    INVESTIGATIONAL NEW DRUGS, 2018, 36 (02) : 332 - 339
  • [36] Characteristics of patients with sorafenib-treated advanced hepatocellular carcinoma eligible for second-line treatment
    Sadahisa Ogasawara
    Tetsuhiro Chiba
    Yoshihiko Ooka
    Eiichiro Suzuki
    Takahiro Maeda
    Masayuki Yokoyama
    Toru Wakamatsu
    Masanori Inoue
    Tomoko Saito
    Kazufumi Kobayashi
    Soichiro Kiyono
    Masato Nakamura
    Shingo Nakamoto
    Shin Yasui
    Akinobu Tawada
    Makoto Arai
    Tatsuo Kanda
    Hitoshi Maruyama
    Osamu Yokosuka
    Naoya Kato
    Investigational New Drugs, 2018, 36 : 332 - 339
  • [37] Cost-effectiveness of Pembrolizumab as Second-line Therapy for the Treatment of Locally Advanced or Metastatic Urothelial Carcinoma in Sweden
    Srivastava, Tushar
    Prabhu, Vimalanand S.
    Li, Haojie
    Xu, Ruifeng
    Zarabi, Natalie
    Zhong, Yichen
    Pellissier, James M.
    Perini, Rodolfo F.
    de Wit, Ronald
    Mamtani, Ronac
    EUROPEAN UROLOGY ONCOLOGY, 2020, 3 (05): : 663 - 670
  • [38] Second-line treatment of postmenopausal women with advanced breast carcinoma
    Board, Ruth E.
    Dean, Emma J.
    Mitchell, Claire
    Wardley, Andrew M.
    EXPERT REVIEW OF ANTICANCER THERAPY, 2006, 6 (04) : 613 - 624
  • [39] Lenalidomide as second-line therapy for advanced hepatocellular carcinoma (HCC): biomarker exploration
    Shao, Y-Y.
    Chen, B-B.
    Lin, Z-Z.
    Hsu, C-H.
    Wang, M-J.
    Cheng, A-L.
    Hsu, C.
    ANNALS OF ONCOLOGY, 2016, 27
  • [40] Immunotherapy versus biologics as second-line therapy in advanced hepatocellular carcinoma (HCC)
    Al-Jumayli, Mohammed
    Hildebrand, Hannah
    Abbasi, Saqib
    Kasi, Anup
    Saeed, Anwaar
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (04)
12345